Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction

Gene Therapy

Volumn 12, Issue 2, 2005, Pages 129-139

  Okada, N ^a   Mori, N ^a   Koretomo, R ^a   Okada, Y ^b   Nakayama, T ^c   Yoshie, O ^c   Mizuguchi, H ^d   Hayakawa, T ^d   Nakagawa, S ^e   Mayumi, T ^e   Fujita, T ^a   Yamamoto, A ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

CCR7; Dendritic cell based vaccination; Malenoma; Migration; RGD fiber mutant adenovirus vector

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; CHEMOKINE RECEPTOR CCR7; CHEMOTACTIC PEPTIDE; DENDRITIC CELL VACCINE; SECONDARY LYMPHOID TISSUE CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CHEMOTAXIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENETIC ENGINEERING; GENETIC TRANSDUCTION; IMMUNOGENICITY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MELANOMA CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; CELL LINE; CELL MOVEMENT; DENDRITIC CELLS; FEMALE; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; LYMPH NODES; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, CHEMOKINE; SKIN NEOPLASMS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE;

EID: 19944430104     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302358     Document Type: Article

References (44)

1. Nestle FO et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4 328-332.
2. Thurner B et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678.
3. Lodge PA et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829-833.
4. Yu JS et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842-847.
5. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
6. Steinman RM et al. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol 1999; 60: 562-567.
7. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001; 106: 255-258.
8. Gunn MD et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189: 451-460.
9. Förster R et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99: 23-33.
10. Arthur JF et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 1997; 4: 17-25.
11. Okada N et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun 2001; 282: 173-179.
12. Okada N et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61: 7913-7919.
13. Okada N et al. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther 2003; 10: 421-431.
14. Okada N et al. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Therapy 2003; 10: 1891-1902.
15. Lanzavecchia A. Identifying strategies for immune intervention. Science 1993; 260: 937-944.
16. Lappin MB et al. Analysis of mouse dendritic cell migration in vivo upon subcutaneous and intravenous injection. Immunology 1999; 98: 181-188.
17. Martín-Fontecha A et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198: 615-621.
18. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 2003; 170: 2817-2823.
19. Granucci F et al. Early events in dendritic cell maturation induced by LPS. Microbes Infect 1999; 1: 1079-1084.
20. Dhodapkar MV et al. Antigen-specific inhibition of effector T cell function in human after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238.
21. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99: 351-358.
22. + anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99: 2468-2476.
23. Mahnke K et al. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002; 80: 477-483.
24. Huang FP et al. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000; 191: 435-444.
25. Hemmi H et al. Skin antigens in the steady state are trafficked to regional lymph nodes by transforming growth factor-β1-dependent cells. Int Immunol 2001; 13: 695-704.
26. Yanagawa Y, Onoe K. CCR7 ligands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 2003; 101: 4923-4929.
27. Saeki H, Moore AM, Brown MJ, Hwang ST. Secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 1999; 162: 2472-2475.
28. Curiel-Lewandrowski C et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macropharge colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163: 174-183.
29. Hirao M et al. CC chemokine receptor-7 on dendritic cell is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes. Cancer Res 2000; 60: 2209-2217.
30. Wu MT, Hwang ST. CXCR5-transduced bone marrow-derived dendritic cells traffic to B cell zones of lymph nodes and modify antigen-specific immune responses. J Immunol 2002; 168: 5096-5102.
31. Nakamura M et al. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res 2002; 8: 2742-2749.
32. de Vries IJM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12-17.
33. Eggert AAO et al. Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett 2003; 89 17-24.
34. Scandella E et al. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100: 1354-1361.
35. Scandella E et al. CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 2004; 103: 1595-1601.
36. 2. Cancer Sci 2003; 94: 1091-1098.
37. Nair S et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003; 171: 6275-6282.
38. Pfeifer JD et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993; 361: 359-362.
39. Okabe M et al. Green mice as a source of ubiquitous green cells. FEBS Lett 1997; 407: 313-319.
40. Mizuguchi H et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Therapy 2001; 8: 730-735.
41. Mizuguchi H, Kay MA. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther 1998; 9: 2577-2583.
42. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther 1999; 10: 2013-2017.
43. Lutz MB et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
44. Okada N et al. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 2001; 84: 1564-1570.